Does inflammation increase hepcidin via IL-6 and reduce iron availability?

The physiological relationship between inflammation and iron metabolism is well-defined, primarily driven by the peptide hormone hepcidin. In inflammatory states, systemic iron availability is significantly restricted through a specific molecular pathway that can lead to functional iron deficiency, even when total body iron stores are adequate or elevated.

Mechanistic explanations

The link between inflammation and hepcidin is primarily mediated by the pro-inflammatory cytokine Interleukin-6 (IL-6).

• The IL-6/STAT3 Pathway: During inflammation, elevated IL-6 levels activate the Janus kinase (JAK)/STAT3 signaling pathway. Specifically, IL-6 binds to its receptor complex, leading to the phosphorylation of STAT3. Once activated, STAT3 translocates to the nucleus and binds directly to the promoter of the HAMP gene, which encodes hepcidin. This specific pathway is necessary and sufficient for the rapid induction of hepcidin during an inflammatory response.
• Ferroportin Degradation: Hepcidin acts as the master regulator of systemic iron by binding to ferroportin, the only known cellular iron exporter. This binding triggers the internalization and lysosomal degradation of ferroportin.
• Sequestration vs. Absorption: By degrading ferroportin on the surface of duodenal enterocytes and macrophages, hepcidin simultaneously blocks dietary iron absorption and prevents the release of recycled iron from macrophages. This results in iron being "locked" within cells, a state known as functional iron deficiency.

Clinical evidence and effectiveness

Clinical data consistently show that elevated hepcidin is the strongest predictor of reduced iron incorporation into red blood cells.

• Isotope Tracer Studies: Research using iron isotopes demonstrates a dose-dependent inhibition of iron absorption as hepcidin levels rise.
• Anemia of Chronic Disease (ACD): In patients with inflammatory conditions (e.g., rheumatoid arthritis or chronic infections), serum iron levels drop significantly (hypoferremia) while ferritin (a storage protein) remains normal or high. This confirms that the issue is not a lack of total iron, but a lack of available iron for erythropoiesis.
• Therapeutic Validation: Clinical trials utilizing anti-IL-6 receptor treatments (such as tocilizumab) have shown that blocking this signaling pathway successfully reduces serum hepcidin levels and improves hemoglobin levels, reinforcing the causality of the IL-6-hepcidin axis.

Bottom line

Inflammation increases hepcidin via IL-6/STAT3 signaling, which degrades ferroportin and sequestrates iron within cells. This process restricts systemic iron availability and dietary absorption, causing functional iron deficiency regardless of total body iron stores.